Government
On Friday, President Donald Trump signed four executive orders in hopes of lowering prescription drug prices in the United States, which was a 2016 campaign promise.
The U.S. Food and Drug Administration (FDA) approved Kite Pharma’s Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). Kite is a Gilead Science company.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
The Prescription Drug User Fee Act (PDUFA) was first passed into law by the U.S. Congress in 1992.
This morning, AstraZeneca announced the approval of the triple-therapy Breztri Aerosphere as a maintenance treatment for COPD.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
“Hopefully the approval process will go very quickly, and we think we have a winner here,” Trump told White House reporters on Wednesday.
The U.S. Food and Drug Administration (FDA) approved Xywav, the first new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.
Two Chinese nationals have been indicted for hacking into the computer systems of hundreds of companies, governments, non-governmental organizations and more to steal trade secrets, including data on treatments related to COVID-19.
PRESS RELEASES